Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAetna implantable hormone pellets Coverage | OpenP…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0345

    Implantable Hormone Pellets

    Customize your policy alerts

    Sign up for Aetna Policy 0345 alerts

    Get alerted when Policy 0345 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for implantable hormone pellets (estradiol, testosterone, progestin/progesterone), including medically necessary indications for testosterone pellets and investigational/noncovered uses. Applies to Aetna members and providers submitting claims for these implants.

    Policy Summary
    PayerAetna
    PolicyImplantable Hormone Pellets
    Policy CodePolicy 0345
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionObtain and document two consecutive fasting morning total serum testosterone measurements (or other specified lab criteria) to support medical necessity for testosterone pellet therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11980CPT for pellet implantation
    S0189HCPCS for 75 mg pellet

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    75 mg
    Testopel strength
    2Required morning tests
    300 ng/dLTotal T threshold

    Coverage Criteria for Implantable Hormone Pellets

    inv-01: Initial medically necessary indications for testosterone pellets

    Aetna considers testosterone propionate implant pellets (Testopel) medically necessary for any of the following indications when the criteria below are met:

    Medically necessary indications

    • Gender dysphoria criteria: Member has a diagnosis of gender dysphoria; and member is able to make an informed decision to engage in hormone therapy; and member's comorbid conditions are reasonably controlled; and member has been educated on contraindications and side effects to therapy; and before the start of therapy the member has been informed of fertility preservation options; and for members <18, medication prescribed by or in consultation with a provider specialized in care of transgender youth who has collaborated care with a mental health care provider, and member has reached or previously reached Tanner stage 2 or greater.

      All listed gender dysphoria conditions must be met

    • Primary or hypogonadotropic hypogonadism criteria: Before the start of testosterone therapy, member has at least two confirmed low morning testosterone levels according to current practice guidelines or laboratory reference values; OR for continuation of testosterone therapy, before the member started therapy the member had a confirmed low morning testosterone level according to current practice guidelines or laboratory reference values.two low morning testosterone levels (initial) or prior confirmed low morning level (continuation)

      Documentation of low serum testosterone is not required after bilateral orchiectomy

    inv-02: Experimental / Investigational (Testosterone)

    Aetna considers implantable testosterone pellets experimental and investigational for the following (not an all-inclusive list):

    Experimental/Investigational indications: Hypogonadism due to aging (age-related or late-onset hypogonadism); Idiopathic hypogonadism not due to disorders of the testicles, pituitary gland or brain; Male menopause; Pain management in women; Treatment of cancers (e.g., breast, kidney, prostate); Treatment of symptoms associated with menopause (unlabeled use).

    Effectiveness has not been established for these indications.

    inv-03: Experimental / Investigational (Estradiol, Progestin)

    Aetna considers implantable estradiol pellets and progestin/progesterone pellets experimental and investigational because effectiveness and safety have not been established for the listed uses:

    Estradiol pellets: Implantable estradiol pellets are experimental/investigational due to unpredictable and fluctuating serum estrogen concentrations and lack of established FDA‑approved commercially available formulations in the U.S.

    FDA compassionate IND programs for estrogen pellets have been terminated.

    Progestin/progesterone pellets are experimental/investigational for the treatment of dysmenorrhea and erythema nodosum because effectiveness has not been established.

    inv-04: Laboratory confirmation for testosterone replacement

    Covered when ALL of the following laboratory documentation criteria are met to establish androgen deficiency:

    Laboratory confirmation: Two consecutive fasting morning total serum testosterone levels below the testing laboratory's normal reference range or below 300 ng/dL; OR for persons with total fasting serum testosterone 300–399 ng/dL, two consecutive low free or bioavailable fasting serum testosterone levels below the laboratory reference range or <225 pmol/L (6 ng/dL); OR one fasting total serum testosterone level if severe deficiency (<150 ng/dL). Samples must be morning (drawn between 7:00 a.m. and 10:00 a.m.) and obtained on different days. Testosterone levels should not be measured during acute or subacute illness.see text

    Use laboratory reference ranges where available; documentation exceptions apply (e.g., bilateral orchiectomy).

    Use of implantable hormone pellets for indications where effectiveness has not been established is considered experimental, investigational, or not covered. Examples include age-related (late‑onset) hypogonadism, idiopathic hypogonadism not due to disorders of the testicles, pituitary gland, or brain, male menopause, pain management in women, treatment of various cancers (e.g., breast, kidney, prostate), and treatment of symptoms associated with menopause as an unlabeled/unsubstantiated use. Progestin/progesterone pellets are likewise considered experimental/investigational for indications such as dysmenorrhea and erythema nodosum because effectiveness has not been established.

    Androgen therapy is contraindicated in persons with a diagnosis of prostate cancer or breast cancer. These diagnoses are specifically listed among conditions for which implantable hormone pellet therapy is not appropriate, and corresponding ICD‑10 codes (for example, C61 for malignant neoplasm of prostate and malignant neoplasm of breast codes C50.011–C50.929) are identified as not covered for indications in this Clinical Policy Bulletin.

    This Clinical Policy Bulletin is developed to assist in administering plan benefits and does not constitute an offer of coverage or medical advice. It contains a general description of plan or program benefits and is not a contract; the bulletin may be updated and is subject to change. Providers are responsible for clinical care and should consult plan‑specific documents and authorization resources for current coverage and prior authorization requirements.

    Implantable estradiol pellets are considered experimental and investigational because they are not FDA‑approved in the U.S., and available evidence indicates unpredictable and fluctuating serum estrogen concentrations and insufficient established safety and effectiveness for listed uses. Many other off‑label uses of testosterone or progestin/progesterone pellets (for example, treatment of menopausal symptoms, non‑endocrine indications, or conditions listed above) are likewise considered not medically necessary or investigational.

    Androgen therapy should not be prescribed in the absence of proven androgen deficiency. In line with consensus guidance, testosterone replacement is not recommended for older men per se, men with chronic non‑gonadal disease, or for treatment of non‑specific symptoms unless objective laboratory evidence of deficiency is documented. Contraindications and precautions (including oncology contraindications) should be considered prior to initiation.

    Procedure, HCPCS, and Diagnosis Codes

    Procedure and related codes (covered if selection criteria met)mixedCovered
    11980Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets beneath the skin) [covered for testosterone only - not estradiol].
    20700Manual preparation and insertion of drug-delivery device(s), deep (eg, subfascial) (List separately in addition to code for primary procedure).
    11981Insertion, non-biodegradable drug delivery implant [not covered when used to implant progestin/ progresterone pellets].
    80414Chorionic gonadotropin stimulation panel; testosterone response.
    80415estradiol response.
    84402Testosterone; free.
    84403total.
    84410Testosterone; bioavailable, direct measurement (eg, differential precipitation).
    S0189Testosterone pellet, 75mg.
    ICD-10 codes listed as covered if selection criteria metICD-10Covered
    E23.0Hypopituitarism [hypogonadotropic hypogonadism] [not covered for androgen deficiency due to aging or idiopathic hypogonadism not due to disorders of the testicles, pituitary gland or brain].
    E29.1Testicular hypofunction [primary] [not covered for androgen deficiency due to aging or idiopathic hypogonadism not due to disorders of the testicles, pituitary gland or brain].
    E30.0Delayed puberty [congenital or acquired endogenous androgen absence or deficiency].
    F64.0 - F64.9Gender identity disorders.
    Z87.890Personal history of sex reassignment.
    ICD-10 codes listed as not covered for indications in CPBICD-10Not Covered
    C50.011 – C50.929Malignant neoplasm of breast.
    C61Malignant neoplasm of prostate.
    C64.1 – C64.9Malignant neoplasm of kidney, except renal pelvis.
    L52Erythema nodosum.
    N50.89Other specified disorders of male genital organs [male menopause].
    N91.0 - N93.9Disorders of menstruation and other abnormal bleeding.
    N94.4 - N94.6Dysmenorrhea.
    N95.0 - N95.9Menopausal and other perimenopausal disorders.
    Z85.43Personal history of malignant neoplasm of ovary
    inv-13: Confirmed low morning testosterone levels — requirement summary
    RequirementAt least two confirmed low morning (fasting) total serum testosterone measurements on different days between 7:00 and 10:00 a.m. prior to initiating testosterone therapy (except after bilateral orchiectomy where not required).
    Sample conditionsSamples must be fasting morning specimens obtained on different days between 7:00 and 10:00 a.m.
    Continuation therapyFor continuation, documentation that a confirmed low morning testosterone level existed before therapy was started is acceptable.
    ExceptionA single morning total testosterone measurement is sufficient if severe deficiency is present (<150 ng/dL).
    inv-14: Total serum testosterone thresholds (<300 ng/dL; <150 ng/dL severe)

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for testosterone pellet implantation (CPT 11980; HCPCS S0189). Provide documentation of the clinical indication and required laboratory proof (see items). Failure to include required lab documentation may result in denial.

    • Prior authorization required for implantation of testosterone pellets (CPT 11980; HCPCS S0189).
    • Include clinical indication supporting medical necessity (e.g., primary or hypogonadotropic hypogonadism, delayed puberty, or gender dysphoria when criteria met).
    • Failure to submit required laboratory documentation (see documentation callout) risks claim denial.
    Documentation Required

    Laboratory Documentation Requirement

    Documentatory proof of androgen deficiency is required for authorization except where noted (bilateral orchiectomy). Two consecutive fasting morning testosterone measurements are required as specified below. If total testosterone is <150 ng/dL (severe deficiency), one fasting morning total testosterone may suffice. Testosterone levels should not be measured during acute or subacute illness.

    Background and Rationale

    Implantable estradiol pellets are not FDA‑approved in the United States and have been judged to produce unpredictable, fluctuating serum estrogen concentrations; therefore their safety and effectiveness for the listed indications have not been established. For testosterone implants, Aetna requires objective laboratory confirmation of androgen deficiency (see laboratory criteria), and clinical guidance notes that therapy should be initiated only after deficiency is proven and that implants carry unique risks (for example, site infection, extrusion) and general risks of androgen therapy (cardiovascular, thromboembolic, hepatic, prostatic, and effects on fertility).

    Definitions and Key Terms

    inv-29: Gender dysphoria — when testosterone pellets may be medically necessary with listed criteria
    IndicationGender dysphoria diagnosis — testosterone pellets may be medically necessary when all listed criteria are met.
    Informed decision-makingMember is able to make an informed decision to engage in hormone therapy.
    Comorbidity control and educationMember's comorbid conditions are reasonably controlled and member has been educated on contraindications and side effects; member informed of fertility preservation options before start of therapy.
    Pediatric requirementFor members <18 years, medication prescribed by or in consultation with a provider specialized in transgender youth care with collaboration of a mental health provider, and member has reached or previously reached Tanner stage 2 or greater.
    inv-30: Androgen deficiency (laboratory definition) — two consecutive low fasting totals or alternate criteria
    Policy Summary
    PayerAetna
    PolicyImplantable Hormone Pellets
    Policy CodePolicy 0345
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionObtain and document two consecutive fasting morning total serum testosterone measurements (or other specified lab criteria) to support medical necessity for testosterone pellet therapy.
    SourceLink
    On This Page
    Coverage Criteria for Implantable Hormone PelletsProcedure, HCPCS, and Diagnosis CodesProvider Actions, Prior Authorization, and DocumentationBackground and RationaleDefinitions and Key Terms
    Low total testosterone thresholdTotal serum testosterone <300 ng/dL is considered low (requires two consecutive fasting morning samples).
    Severe deficiency thresholdTotal serum testosterone <150 ng/dL — one fasting morning sample is sufficient to document severe deficiency.
    Use of reference rangesLaboratory reference ranges should be used where available; the <300 ng/dL threshold applies when reference ranges are not provided.
    inv-15: Free/bioavailable testosterone threshold when total is low-normal
    When requiredIf total testosterone is in the low‑normal range (300–399 ng/dL), obtain two consecutive low free or bioavailable fasting testosterone levels to document deficiency.
    Free/bioavailable thresholdFree or bioavailable testosterone below the testing laboratory's reference range or <225 pmol/L (6 ng/dL) if reference ranges are not available.
    Sample requirementsFree/bioavailable measurements must be fasting morning samples obtained on different days between 7:00 and 10:00 a.m.
    • Laboratory proof required for authorization: two consecutive fasting morning samples between 7:00 and 10:00 on different days.
    • Acceptable tests: total testosterone (preferred); if total is low-normal (301–399 ng/dL), provide two consecutive low free or bioavailable fasting serum testosterone levels.
    • One fasting morning total testosterone is sufficient when total <150 ng/dL (severe deficiency).
    • Do not measure levels during acute/subacute illness; use reference laboratory ranges to interpret results.
    Note

    Provider Actions — Therapy Considerations and Step Therapy

    Implantable testosterone pellets are considered a second-line replacement therapy option. Initiate testosterone therapy only after androgen deficiency has been demonstrated by laboratory assays and after counseling regarding risks, contraindications, and fertility preservation when applicable. There are no specified step-therapy requirements in this policy.

    • Implantable testosterone pellets may be used as second-line testosterone replacement therapy after proven androgen deficiency.
    • Initial therapy considerations: start therapy only after at least two confirmed low morning testosterone levels (or as noted for severe deficiency); tailor maintenance modality (injections, implants, capsules) to patient needs.
    • No step therapy requirements specified in this policy.
    Denial Risk

    Coverage Limits, Documentation, and Administrative Information

    Procedures or indications outside the listed medically necessary testosterone indications (e.g., age-related hypogonadism, idiopathic hypogonadism not due to testicular/pituitary/brain disorders, treatment of menopause symptoms, cancer treatment, pain management in women) are not covered. Administrative links for policy history and additional information are available in the policy header.

    • Procedures/indications outside the listed medically necessary testosterone indications are not covered.
    • Documentation for primary or hypogonadotropic hypogonadism: two confirmed low morning levels per current practice guidelines or lab reference ranges.
    • Administrative: see policy history and Clinical Policy Bulletin Notes for updates; this policy is not a contract and may be updated.
    Primary laboratory definitionTwo consecutive fasting morning total serum testosterone levels below the testing laboratory's reference range or below 300 ng/dL (drawn between 7:00 and 10:00 a.m. on different days).
    Alternative when total low-normalIf total testosterone is 300–399 ng/dL, two consecutive low free or bioavailable fasting testosterone levels (below reference range or <225 pmol/L/6 ng/dL) are required.
    Severe deficiencyOne fasting morning total serum testosterone level is sufficient if <150 ng/dL.
    inv-31: Contraindications/precautions — prostate/breast cancer; other precautions listed
    Absolute contraindicationsKnown prostate cancer or breast cancer (androgen therapy is contraindicated).
    PrecautionsAndrogen-sensitive epilepsy, migraine, sleep apnea, polycythemia, and fluid overload should be considered when prescribing testosterone.
    Older adults and puberty inductionUse lower starting doses for older men; caution with induction of puberty and avoid IM injections in men with bleeding disorders.
    Fertility and athletic considerationsCounsel regarding potential impact on fertility; competitive athletes should be warned about disqualification risks with androgen use.